The purpose of this study was to determine whether orlistat is effective in decreasing plasma unconjugated bilirubin levels in patients with Crigler-Najjar disease.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
decrease in plasma unconjugated bilirubin level during orlistat
increase in fecal fat excretion during orlistat
increase in fecal bilirubin concentration during orlistat